Skip to main content
SpringerLink
Log in

Alectinib/crizotinib

Acquired drug resistance and off-label use: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Singh H, et al. Molecular characterization and therapeutic targeting of colorectal cancers harboring receptor tyrosine kinase fusions. Clinical Cancer Research 27: 1695-1705, No. 6, Mar 2021. Available from: URL: http://doi.org/10.1158/1078-0432.CCR-20-4073

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alectinib/crizotinib. Reactions Weekly 1856, 23 (2021). https://doi.org/10.1007/s40278-021-96016-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-96016-6

Search

Navigation